Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.5.1.88 - peptide deformylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Anemia, Hypochromic
Inhibition of peptide deformylase in Nicotiana tabacum leads to decreased D1 protein accumulation, ultimately resulting in a reduction of photosystem II complexes
Inhibition of peptide deformylase in Nicotiana tabacum leads to decreased D1 protein accumulation, ultimately resulting in a reduction of photosystem II complexes.
Bacterial Infections
Chronicles in drug discovery.
Burkitt Lymphoma
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Infections
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Inhibition of chlamydial infection in the genital tract of female mice by topical application of a peptide deformylase inhibitor.
Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers.
Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Quantification of IDP-73152, a novel antibiotic, in plasma from mice, rats and humans using an ultra-high performance liquid chromatography/tandem mass spectrometry method for use in pharmacokinetic studies.
Leukemia, Myeloid, Acute
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Lung Neoplasms
Overexpression of peptide deformylase in breast, colon, and lung cancers.
Malaria
An improved crystal form of Plasmodium falciparum peptide deformylase.
Neoplasms
A new human peptide deformylase inhibitable by actinonin.
Chronicles in drug discovery.
High-throughput identification of inhibitors of human mitochondrial peptide deformylase.
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Overexpression of peptide deformylase in breast, colon, and lung cancers.
Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells.
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target.
Structure-Based Drug Design of Small Molecule Peptide Deformylase Inhibitors to Treat Cancer.
Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
Pneumonia
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Pneumonia, Bacterial
In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Pneumonia, Pneumococcal
Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Respiratory Tract Diseases
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Respiratory Tract Infections
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers.
Soft Tissue Infections
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Tuberculosis
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.
Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics.
Glycine in the conserved motif III modulates the thermostability and oxidative stress resistance of peptide deformylase in Mycobacterium tuberculosis.
Identification of regions involved in enzymatic stability of peptide deformylase of Mycobacterium tuberculosis.
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
The carboxy-terminal end of the peptide deformylase from Mycobacterium tuberculosis is indispensable for its enzymatic activity.
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Three consecutive arginines are important for the mycobacterial peptide deformylase enzyme activity.